PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company’s petition for en banc review of the U.S. Court of Appeals for the Federal Circuit’s decision in The Medicines Company v. Hospira, Inc. was granted. This vacates the Court’s earlier decision invalidating the Orange Book patents covering Angiomax® that expire in 2028 (pediatric exclusivity expiring in 2029). The Court requested briefing concerning the commercial on-sale bar issue. It has requested the views of the United States Department of Justice, and will also allow other amicus curiae to submit their views.
Help employers find you! Check out all the jobs and post your resume.
